Oncopeptides AB (publ) (STO:ONCO)

Oncopeptides AB Statistics

Total Valuation

Oncopeptides AB has a market cap or net worth of SEK 1.06 billion. The enterprise value is 1.12 billion.

Market Cap	1.06B
Enterprise Value	1.12B

Important Dates

The last earnings date was Thursday, August 21, 2025.

Earnings Date	Aug 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Oncopeptides AB has 225.76 million shares outstanding. The number of shares has decreased by -1.40% in one year.

Current Share Class	211.26M
Shares Outstanding	225.76M
Shares Change (YoY)	-1.40%
Shares Change (QoQ)	+0.14%
Owned by Insiders (%)	0.71%
Owned by Institutions (%)	19.28%
Float	182.36M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	20.75
PB Ratio	-15.78
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.20
EV / Sales	22.06
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.45

Financial Position

The company has a current ratio of 1.72

Current Ratio	1.72
Quick Ratio	1.61
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.42
Interest Coverage	-14.47

Financial Efficiency

Return on equity (ROE) is -423.80% and return on invested capital (ROIC) is -85.90%.

Return on Equity (ROE)	-423.80%
Return on Assets (ROA)	-55.09%
Return on Invested Capital (ROIC)	-85.90%
Return on Capital Employed (ROCE)	-370.33%
Revenue Per Employee	678,267
Profits Per Employee	-3.56M
Employee Count	80
Asset Turnover	0.17
Inventory Turnover	0.29

Taxes

In the past 12 months, Oncopeptides AB has paid 517,000 in taxes.

Income Tax	517,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +117.96% in the last 52 weeks. The beta is -1.13, so Oncopeptides AB's price volatility has been lower than the market average.

Beta (5Y)	-1.13
52-Week Price Change	+117.96%
50-Day Moving Average	3.73
200-Day Moving Average	2.16
Relative Strength Index (RSI)	51.81
Average Volume (20 Days)	5,724,036

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncopeptides AB had revenue of SEK 50.87 million and -267.18 million in losses. Loss per share was -1.26.

Revenue	50.87M
Gross Profit	49.13M
Operating Income	-259.74M
Pretax Income	-266.66M
Net Income	-267.18M
EBITDA	-257.26M
EBIT	-259.74M
Loss Per Share	-1.26

Balance Sheet

The company has 70.15 million in cash and 137.02 million in debt, giving a net cash position of -66.87 million or -0.30 per share.

Cash & Cash Equivalents	70.15M
Total Debt	137.02M
Net Cash	-66.87M
Net Cash Per Share	-0.30
Equity (Book Value)	-66.88M
Book Value Per Share	-0.30
Working Capital	47.80M

Cash Flow

In the last 12 months, operating cash flow was -324.71 million and capital expenditures -357,000, giving a free cash flow of -325.07 million.

Operating Cash Flow	-324.71M
Capital Expenditures	-357,000
Free Cash Flow	-325.07M
FCF Per Share	-1.44

Margins

Gross Margin	96.58%
Operating Margin	-510.60%
Pretax Margin	-524.20%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oncopeptides AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.40%
Shareholder Yield	n/a
Earnings Yield	-25.31%
FCF Yield	-30.80%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1